Cancer UrologyCancer UrologyОнкоурология1726-97761996-1812Publishing House ABV Press45610.17650/1726-9776-2015-11-2-69-76PROSTATE CANCERРАК ПРЕДСТАТЕЛЬНОЙ ЖЕЛЕЗЫBrachytherapy for prostate cancer: Comparative characteristics of proceduresБрахитерапия рака предст ательной железы: сравнительная характеристика методикKanaevS. V.КанаевС. В.
Russian Federation
NovikovS. N.НовиковС. Н.
Russian Federation
NovikovR. V.НовиковР. В.
Russian Federation
novikov-spb@mail.ruNosovA. K.НосовА. К.
Russian Federation
PetrovS. B.ПетровС. Б.
Russian Federation
RevaS. A.РеваС. А.
Russian Federation
Department of Radiotherapy and Radionuclide Diagnosis N. N. Petrov Research Institute of Oncology, Ministry of Health of RussiaОтделение радиотерапии и радионуклидной диагностики ФГБУ «НИИ онкологии им. Н. Н. Петрова» Минздрава России68, Leningradskaya St., Pesochnyi Settlement, Saint Petersburg 197758, RussiaРоссия, 197758, Санкт-Петербург, пос. Песочный, ул. Ленинградская, 68Department of Urologic Oncology, N. N. Petrov Research Institute of Oncology, Ministry of Health of Russiaотделение онкоурологии ФГБУ «НИИ онкологии им. Н. Н. Петрова» Минздрава России3006201511269761906201519062015https://oncourology.abvpress.ru/oncur/article/view/456

The introduction of interstitial radiation sources is the «youngest» of the radical method of treatment of patients with prostate cancer (PC). The high level of efficiency comparable to prostatectomy at a significantly lower rate of complications causes rapid growth of clinical use of brachytherapy (BT). Depending on the radiation source and the mode of administration into the prostate gland are two types BT – high-dose rate (temporary) (HDR-BT) and low-dose rate (permanent) (LDR-BT) brachytherapy. At the heart of these two methods are based on a single principle of direct effect of the quantum gamma radiation on the area of interest. However, the differences between the characteristics of isotopes used and technical aspects of the techniques cause the difference in performance and complication rates for expression HDR-BT and LDR-BT.

Внутритканевое введение источников излучения является самым «молодым» методом радикального лечения больных раком предстательной железы (РПЖ). Высокий уровень эффективности, сопоставимый с простатэктомией при существенно более низкой частоте осложнений обусловливает стремительный рост клинического использования брахитерапии (БТ). В зависимости от мощности источника излучения и способа его введения в предстательную железу различают два вида БТ – высокодозную (ВДБТ), характеризующуюся кратковременным внутритканевым введением источника высокой мощности дозы (временную), и низкодозную (НДБТ), при которой осуществляется перманентная установка источника низкой мощности дозы (постоянную). В основе этих 2 методов лежит единый принцип введения источника гамма-излучения непосредственно в опухоль. Вместе с тем методические и технические особенности ВДБТ и НДБТ обусловливают существенные различия в показаниях к их использованию, эффективности у больных с различной распространенностью и агрессивностью опухолевого процесса, а также в частоте, характере, степени выраженности и продолжительности нежелательных эффектов лечения.

prostate cancerbrachytherapyhigh dose rate brachytherapylow dose rate brachytherapyinterstitial radiation therapycontact radiation therapyclinical recommendationsрак предстательной железыбрахитерапиявысокодозная брахитерапиянизкодозная брахитерапияинтерстициальная лучевая терапияконтактная лучевая терапияклинические рекомендации1. Forsstell G. La lutte social contre le cancer. J de Radiologie 1931;15.Forsstell G. La lutte social contre le cancer. J de Radiologie 1931;15.2. Minet H. Applications du radium aux tumeurs, a l´hypertrophie et au cancer de la prostate, etc. Proc Verb Mem Assoc Franc Urol 1909;13:629–46.Minet H. Applications du radium aux tumeurs, a l´hypertrophie et au cancer de la prostate, etc. Proc Verb Mem Assoc Franc Urol 1909;13:629–46.3. Desnos E. Action du radium sur la prostate hypertrophiee. Proc Verb Mem Assoc Franc Urol 1909;13:646–56.Desnos E. Action du radium sur la prostate hypertrophiee. Proc Verb Mem Assoc Franc Urol 1909;13:646–56.4. Barringer B. S. Radium in the treatment of carcinoma of the bladder and prostate. JAMA 1916;68;1227–30.Barringer B. S. Radium in the treatment of carcinoma of the bladder and prostate. JAMA 1916;68;1227–30.5. Duane W. Methods of preparing and using radioactive substances in the treatment of malignant diseases, and of estimating suitable dosages. Boston Med Surg J 1917;177:787–99.Duane W. Methods of preparing and using radioactive substances in the treatment of malignant diseases, and of estimating suitable dosages. Boston Med Surg J 1917;177:787–99.6. Arnowitz J. N. Buried emanation: the development of seeds for permanent implantation. Brachytherapy 2002; 1:167–78.Arnowitz J. N. Buried emanation: the development of seeds for permanent implantation. Brachytherapy 2002; 1:167–78.7. Failla G. Radium technique at the Memorial Hospital, New York. Arch Radiol Electrother 1920;25:3–19.Failla G. Radium technique at the Memorial Hospital, New York. Arch Radiol Electrother 1920;25:3–19.8. Arnowitz J. N. Don Lawrence and the “ K-capture” revolution. Brachytherapy 2010;9:373–81.Arnowitz J. N. Don Lawrence and the “ K-capture” revolution. Brachytherapy 2010;9:373–81.9. Whitmore W. F., Hilaris B., Grabstald H. Retropubic implantation to iodine 125 in the treatment of prostate cancer. J Urol 1972;108:918–20.Whitmore W. F., Hilaris B., Grabstald H. Retropubic implantation to iodine 125 in the treatment of prostate cancer. J Urol 1972;108:918–20.10. Holm H. H., Juul N., Pedersen J. F. et al. Transperineal iodine-125 seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983; 130(1):283–86.Holm H. H., Juul N., Pedersen J. F. et al. Transperineal iodine-125 seed implantation in prostatic cancer guided by transrectal ultrasonography. J Urol 1983; 130(1):283–86.11. Blasko J. C., Ragde H., Schumacher D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocuriether Hypertherm Oncol 1987;3:131–9.Blasko J. C., Ragde H., Schumacher D. Transperineal percutaneous iodine-125 implantation for prostatic carcinoma using transrectal ultrasound and template guidance. Endocuriether Hypertherm Oncol 1987;3:131–9.12. D, Amico A. V., Whittington R., Malkowicz S. B. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969–74.D, Amico A. V., Whittington R., Malkowicz S. B. et al. Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998;280(11):969–74.13. Lee L. N., Stock R. G., Stone N. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002;52(2):444–52.Lee L. N., Stock R. G., Stone N. Role of hormonal therapy in the management of intermediate- to high-risk prostate cancer treated with permanent radioactive seed implantation. Int J Radiat Oncol Biol Phys 2002;52(2):444–52.14. Sylvester J. E., Blasko J. C., Grimm P. D. et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 2003; 57(4):944–52.Sylvester J. E., Blasko J. C., Grimm P. D. et al. Ten-year biochemical relapse-free survival after external beam radiation and brachytherapy for localized prostate cancer: the Seattle experience. Int J Radiat Oncol Biol Phys 2003; 57(4):944–52.15. Mohler J., Bahnson R. R., Boston B. et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8(2):162–200.Mohler J., Bahnson R. R., Boston B. et al. NCCN clinical practice guidelines in oncology: prostate cancer. J Natl Compr Canc Netw 2010;8(2):162–200.16. Davis B. J., Horwitz E. M., Lee W. R. et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherahy 2012;11:6–19.Davis B. J., Horwitz E. M., Lee W. R. et al. American Brachytherapy Society consensus guidelines for transrectal ultrasound-guided permanent prostate brachytherapy. Brachytherahy 2012;11:6–19.17. Yamada Y., Rogers L., Demanes D. J. et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherahy 2012; 11(1):20–32.Yamada Y., Rogers L., Demanes D. J. et al. American Brachytherapy Society consensus guidelines for high-dose-rate prostate brachytherapy. Brachytherahy 2012; 11(1):20–32.18. Ash D., Flynn A., Battermann J. et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315–21.Ash D., Flynn A., Battermann J. et al. ESTRO/EAU/EORTC recommendations on permanent seed implantation for localized prostate cancer. Radiother Oncol 2000;57:315–21.19. Hoskin P. J., Colombo A., Henry A. et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: An update. Radiother Oncol 2013;107:325–32.Hoskin P. J., Colombo A., Henry A. et al. GEC/ESTRO recommendations on high dose rate afterloading brachytherapy for localised prostate cancer: An update. Radiother Oncol 2013;107:325–32.20. Heidenreich A., Bellmunt J., Bolla M. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59(1):61–71.Heidenreich A., Bellmunt J., Bolla M. et al. EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 2011;59(1):61–71.21. Skowronek J. Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer – between options. J Contemp Brachyther 2013; 5(1):33–41.Skowronek J. Low-dose-rate or high-dose-rate brachytherapy in treatment of prostate cancer – between options. J Contemp Brachyther 2013; 5(1):33–41.22. Strohmaier S., Zwierzchowski G. Comparison of Co60 and Ir198 sources in HDR brachytherapy. J Contemp Brachyther 2011;3(4):199–208.Strohmaier S., Zwierzchowski G. Comparison of Co60 and Ir198 sources in HDR brachytherapy. J Contemp Brachyther 2011;3(4):199–208.23. Martinez A. A., Gonzalez J., Ye H. et al. Dose escalation improves cancer-related events at 10 years for intermediate- and highrisk prostate cancer patients treated with hypofractionated high- dose rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011;79:363–70.Martinez A. A., Gonzalez J., Ye H. et al. Dose escalation improves cancer-related events at 10 years for intermediate- and highrisk prostate cancer patients treated with hypofractionated high- dose rate boost and external beam radiotherapy. Int J Radiat Oncol Biol Phys 2011;79:363–70.24. Vicini F. A., Vargas C., Edmundson G. et al. The role of high-dose rate brachytherapy in locally advanced prostate cancer. Semin Radiat Oncol 2003;13:98–108.Vicini F. A., Vargas C., Edmundson G. et al. The role of high-dose rate brachytherapy in locally advanced prostate cancer. Semin Radiat Oncol 2003;13:98–108.25. Kunos C. A., Resnick M. I., Kinsella T. J., Ellis R. J. Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator. Int J Radiat Oncol Biol Phys 1997;39(3):667–70.Kunos C. A., Resnick M. I., Kinsella T. J., Ellis R. J. Migration of implanted free radioactive seeds for adenocarcinoma of the prostate using a Mick applicator. Int J Radiat Oncol Biol Phys 1997;39(3):667–70.26. Nag S., Vivekanandam S., Martinez-Monge R. Pulmonary embolization of permanently implanted radioactive palladium 103 seeds for carcinoma of the prostate. Brachytherapy 2004;3(2):71–7.Nag S., Vivekanandam S., Martinez-Monge R. Pulmonary embolization of permanently implanted radioactive palladium 103 seeds for carcinoma of the prostate. Brachytherapy 2004;3(2):71–7.27. Jereczek-Fossa B. A., Orecchia R. Evidence-based radiation oncology: Definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radioth Oncol 2007;84:197–215.Jereczek-Fossa B. A., Orecchia R. Evidence-based radiation oncology: Definitive, adjuvant and salvage radiotherapy for non-metastatic prostate cancer. Radioth Oncol 2007;84:197–215.28. Канаев С. В., Новиков С. Н.Особенности высокодозной брахитерапии больных локализованным раком предстательной железы. Вопросы онкологии 2013;59(5):645–50. [Kanaev S.V., Novikov S.N. Peculiar properties of high dose rate brachytherapy in patients with localized prostate cancer. Voprosy onkologii = Problems in Oncology 2013;59(5):645–50 (In Russ)].Канаев С. В., Новиков С. Н.Особенности высокодозной брахитерапии больных локализованным раком предстательной железы. Вопросы онкологии 2013;59(5):645–50. [Kanaev S.V., Novikov S.N. Peculiar properties of high dose rate brachytherapy in patients with localized prostate cancer. Voprosy onkologii = Problems in Oncology 2013;59(5):645–50 (In Russ)].29. Fowler J., Chappell R., Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50: 1021–31.Fowler J., Chappell R., Ritter M. Is alpha/beta for prostate tumors really low? Int J Radiat Oncol Biol Phys 2001;50: 1021–31.30. Retter M., Forman J., Kupelian P. et al. Hypofractionation for Prostate Cancer. Cancer J 2009;15(1):1–6.Retter M., Forman J., Kupelian P. et al. Hypofractionation for Prostate Cancer. Cancer J 2009;15(1):1–6.31. Macias V., Biete A. Hypofractionated radiotherapy for localised prostate cancer. Reviewofclinicaltrials. ClinTransl Oncol 2009;11:437–45.Macias V., Biete A. Hypofractionated radiotherapy for localised prostate cancer. Reviewofclinicaltrials. ClinTransl Oncol 2009;11:437–45.32. Hoskin P. J., Bownes P. J., Ostler P. et al. High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. Radiother Oncol 2003;6:285–8.Hoskin P. J., Bownes P. J., Ostler P. et al. High dose rate afterloading brachytherapy for prostate cancer: catheter and gland movement between fractions. Radiother Oncol 2003;6:285–8.33. Hoskin P. J., Rojas A. M., Bownes P. J. et al. Randomised trial of external beam radiotherapy alone or combined with highdose- rate brachytherapy boost for localised prostate cancer. Radioth Oncol 2012;103:217–22.Hoskin P. J., Rojas A. M., Bownes P. J. et al. Randomised trial of external beam radiotherapy alone or combined with highdose- rate brachytherapy boost for localised prostate cancer. Radioth Oncol 2012;103:217–22.34. Yoshioka Y., Suzuki O., Otani Y. et al. High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective. J Contemp Brachyther 2014;6(1):91–8.Yoshioka Y., Suzuki O., Otani Y. et al. High-dose-rate brachytherapy as monotherapy for prostate cancer: technique, rationale and perspective. J Contemp Brachyther 2014;6(1):91–8.35. Yoshioka Y., Konishi K., Sumida I. et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: Five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys 2011;80:469–75.Yoshioka Y., Konishi K., Sumida I. et al. Monotherapeutic high-dose-rate brachytherapy for prostate cancer: Five-year results of an extreme hypofractionation regimen with 54 Gy in nine fractions. Int J Radiat Oncol Biol Phys 2011;80:469–75.36. Demanes D. J., Martinez A. A., Ghilezan M. et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol hys 2011;81:1286–92.Demanes D. J., Martinez A. A., Ghilezan M. et al. High-dose-rate monotherapy: safe and effective brachytherapy for patients with localized prostate cancer. Int J Radiat Oncol Biol hys 2011;81:1286–92.37. Martinez A. A., Demanes J., Vargas C. et al. High dose rate prostate brachytherapy: an excellent accelerated hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 2010;33:481–8.Martinez A. A., Demanes J., Vargas C. et al. High dose rate prostate brachytherapy: an excellent accelerated hypofractionated treatment for favorable prostate cancer. Am J Clin Oncol 2010;33:481–8.38. Ghadjar P., Keller T., Pentsch C. A. et al. Toxicity and early treatment outcomes in low and intermediate-risk prostate cancer managed by high-dose rate brachytherapy as monotherapy. Brachytherapy 2009;8:45–51.Ghadjar P., Keller T., Pentsch C. A. et al. Toxicity and early treatment outcomes in low and intermediate-risk prostate cancer managed by high-dose rate brachytherapy as monotherapy. Brachytherapy 2009;8:45–51.39. Hoskin P., Rojas A., Lowe G. et al. Highdose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys 2012;82:1376–84.Hoskin P., Rojas A., Lowe G. et al. Highdose-rate brachytherapy alone for localized prostate cancer in patients at moderate or high risk of biochemical recurrence. Int J Radiat Oncol Biol Phys 2012;82:1376–84.40. Zamboglou N., Tselis N., Baltas D. et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 2013;85:672–8.Zamboglou N., Tselis N., Baltas D. et al. High-dose-rate interstitial brachytherapy as monotherapy for clinically localized prostate cancer: treatment evolution and mature results. Int J Radiat Oncol Biol Phys 2013;85:672–8.41. Rogers C. L., Alder S. C., Rogers R. L. et al. High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol 2012;187:109–16.Rogers C. L., Alder S. C., Rogers R. L. et al. High dose brachytherapy as monotherapy for intermediate risk prostate cancer. J Urol 2012;187:109–16.42. Ellis R. J., Zhou H., Kim E. Y. et al. Biochemical diseasefree survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. Brachytherapy 2007:6(1):16–25.Ellis R. J., Zhou H., Kim E. Y. et al. Biochemical diseasefree survival rates following definitive low-dose-rate prostate brachytherapy with dose escalation to biologic target volumes identified with SPECT/CT capromab pendetide. Brachytherapy 2007:6(1):16–25.43. Zelefsky M. J., Kuban D. A., Levy L. B. et al. Multiinstitutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67:327–33.Zelefsky M. J., Kuban D. A., Levy L. B. et al. Multiinstitutional analysis of long-term outcome for stages T1–T2 prostate cancer treated with permanent seed implantation. Int J Radiat Oncol Biol Phys 2007;67:327–33.44. Khaksar S. J., Laing R. W., Henderson A. et al. Biochemical (prostatespecific antigen) relapse-free survival and toxicity after 125I low-dose rate prostate brachytherapy. BJU Int 2006;98:1210–5.Khaksar S. J., Laing R. W., Henderson A. et al. Biochemical (prostatespecific antigen) relapse-free survival and toxicity after 125I low-dose rate prostate brachytherapy. BJU Int 2006;98:1210–5.45. Guedea F., Aguilo F., Polo A. et al. Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1–T2 prostate cancer. Radiother Oncol 2006;1:57–61.Guedea F., Aguilo F., Polo A. et al. Early biochemical outcomes following permanent interstitial brachytherapy as monotherapy in 1050 patients with clinical T1–T2 prostate cancer. Radiother Oncol 2006;1:57–61.46. Potters L., Morgenstern C., Calugaru E. et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005;173:1562–6.Potters L., Morgenstern C., Calugaru E. et al. 12-year outcomes following permanent prostate brachytherapy in patients with clinically localized prostate cancer. J Urol 2005;173:1562–6.47. Stone N. N., Stone M. M., Rosenstein B. S. et al. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol 2011;185(2):495–500.Stone N. N., Stone M. M., Rosenstein B. S. et al. Influence of pretreatment and treatment factors on intermediate to long-term outcome after prostate brachytherapy. J Urol 2011;185(2):495–500.